Document text
Principal Investigator: Adolfo Garcia-Sastre
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2024
Award: $599,601
Funding agency: National Cancer Institute
Project Summary/Abstract
The Mount Sinai U54 continues to accrue new lung cancer (LC) patients to its large, highly annotated
longitudinal cohort with routine specimen collection. Updated research focus areas include: 1) the ability
of patients with lung cancer to maintain robust immune responses to infections and/or vaccinations related
to novel variants; 2) the long-term health consequences of SARS-CoV-2 infection in patients with lung
cancer; and 3) biologic factors that influence SARS-CoV-2 susceptibility using in vitro modeling. The
magnitude, quality, breadth and durability of the systemic and mucosal immune responses elicited by
influenza virus and RSV vaccinations will be determined in comparison to SARS-CoV-2 in LC patients.
Key areas to be addressed here include the effects of: vaccine platform, timing of vaccination, concordance
or discordance of patient immune response to differing vaccines, a more detailed understanding of the
effects of cancer treatment, and the correlation between cellular and antibody response. The Mount Sinai
finding that vaccination for influenza was associated with a subsequent induction of SARS-CoV-2 anti-
spike Abs in our patients will be validated using patient specimens from collaborators within the Pooling
Project. The Mount Sinai clinical team will continue to Investigate socioeconomic and demographic
associations with the risk of compromised immune responses and/or severe infection. Additionally, residual
plasma from select patients will be used to determine whether patients who experienced a SARS-CoV-2
infection retain molecular evidence of viral infection. Evidence for a persistent reservoir of viral RNA and/or
proteins will be determined by highly sensitive RT-qPCR and ELISA-based assays, and the duration of
persistence after infection will be correlated with specific clinical symptoms.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Antibodies><Antibody Response><Area><Assay><Bioassay><Biologic Factor><Biological Assay><Biological Factors><Blood Plasma><Blood Sample><Blood specimen><COVID-19 infection><COVID-19 predisposition><COVID-19 susceptibility><COVID-19 virus><COVID-19 virus infection><COVID-19 vulnerability><COVID19 infection><COVID19 virus><Cancer Patient><Cancer Treatment><Clinical><CoV-2><CoV2><Consent><Control Groups><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Coupled><Data Bases><Databases><Demographic Factors><ELISA><Enzyme-Linked Immunosorbent Assay><Flu vaccination><Immune response><Immunological response><Infection><Influenza Virus><Influenza immunization><Influenza vaccination><Long-term cohort><Longitudinal cohort><Longterm cohort><Lung immune response><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Tumor of the Lung><Malignant neoplasm of lung><Molecular><Mucosal Immune Responses><Patient Selection><Patients><Plasma><Plasma Serum><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Prophylactic vaccination against influenza><Pulmonary Cancer><Pulmonary malignant Neoplasm><Research><Research Specimen><Residual><Residual state><Reticuloendothelial System, Serum, Plasma><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV-2 predisposition><SARS-CoV-2 susceptibility><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Serology><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Specimen><Symptoms><Update><Vaccination><Vaccines><Variant><Variation><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Viral reservoir><Virus Diseases><Virus reservoir><Wuhan coronavirus><after COVID-19 infection><after SARS-CoV-2 infection><after SARS-CoV2 infection><after infection by SARS-CoV-2><after severe acute respiratory distress syndrome CoV-2 infection><anti-cancer therapy><cancer therapy><cancer-directed therapy><chronic effect of COVID-19><coronavirus disease 2019 infection><coronavirus disease 2019 virus><coronavirus disease-19 virus><data base><enzyme linked immunoassay><experience><flu immunisation><following COVID-19 infection><following SARS-CoV-2 infection><following SARS-CoV2 infection><following infection by SARS-CoV-2><following severe acute respiratory distress syndrome CoV-2 infection><hCoV19><host response><immune system response><immunoresponse><in vitro Model><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><influenza virus vaccination><influenzavirus><long term consequences of COVID-19><long term consequences of SARS-CoV-2 infection><long term consequences of coronavirus disease-19><long term effects of COVID-19><long term health consequences of COVID-19><long term health consequences of SARS-CoV2 infection><long term impact of COVID-19><long term impact of SARS-CoV-2 infection><long-term consequence of severe acute respiratory distress syndrome-cov-2 infection><long-term effects of coronavirus disease-19><longterm consequences of COVID-19><longterm consequences of SARS-CoV-2 infection><longterm effects of COVID-19><longterm health consequences of COVID-19><longterm health consequences of SARS-CoV2 infection><longterm impact of COVID-19><longterm impact of SARS-CoV-2 infection><lung cancer><nCoV2><novel><patient population><post SARS-CoV-2 infection><predisposed to Coronavirus disease 2019><previous COVID-19 infection><previous SARS-CoV-2 infection><previous SARS-CoV2 infection><previous severe acute respiratory distress syndrome CoV-2 infection><prior COVID-19 infection><prior SARS-CoV-2 infection><prior SARS-CoV2 infection><prior severe acute respiratory distress syndrome CoV-2 infection><pulmonary immune response><sample collection><socio-economic><socio-economically><socioeconomically><socioeconomics><specimen collection><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><vaccination against influenza><vaccine platform><viral RNA><viral infection><virus RNA><virus infection><virus protein><virus-induced disease><vulnerable to COVID-19><vulnerable to Coronavirus disease 2019><vulnerable to SARS-CoV-2><vulnerable to Severe acute respiratory syndrome coronavirus 2>